Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Vibrant
Cambridge, Massachusetts, United Statesvibrantx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead masked T cell engager (mTCE) prodrug candidates showing preclinical efficacy and safety; aim to enter clinical trials for solid tumors in 2025; platform allows rapid generation and screening of antibody mutants and prodrugs
- Therapeutic areas
- OncologyImmunology
- Modalities
- Monoclonal antibodyAntibody-drug conjugateBiologicProteinProdrug
- Industry
- Biotech
02
Partnerships
Pursuing out-licensing, co-development, and partnering opportunities; specifics not disclosed
Beyond the preview
Go deeper on Vibrant.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vibrant.